Sana Biotechnology, a company that develops platforms to replace or repair cells in our bodies, wrapped an upsized IPO at $588 million.Morgan Stanley, Goldman Sachs Group, JPMorgan and BofA Securities were the bookrunners for the deal.
How to buy shares in Sana Biotechnology
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – SANA – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Sana Biotechnology stock price (NASDAQ: SANA)Use our graph to track the performance of SANA stocks over time.
Sana Biotechnology shares at a glance
|Latest market close||$20.07|
|52-week range||$16.09 - $44.60|
|50-day moving average||$22.65|
|200-day moving average||$21.78|
|Wall St. target price||$37.50|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-3.98|
Buy Sana Biotechnology shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Sana Biotechnology stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Sana Biotechnology price performance over time
|1 week (2021-10-15)||-3.46%|
|1 month (2021-09-23)||-12.78%|
|3 months (2021-07-23)||8.14%|
|6 months (2021-04-23)||-18.65%|
|1 year (2020-10-19)||N/A|
|2 years (2019-10-19)||N/A|
|3 years (2018-10-19)||N/A|
|5 years (2016-10-19)||N/A|
Sana Biotechnology financials
|Gross profit TTM||$0|
|Return on assets TTM||-25.47%|
|Return on equity TTM||-80.76%|
|Market capitalisation||$3.9 billion|
TTM: trailing 12 months
Shorting Sana Biotechnology shares
There are currently 8.4 million Sana Biotechnology shares held short by investors – that's known as Sana Biotechnology's "short interest". This figure is 32.1% up from 6.4 million last month.
There are a few different ways that this level of interest in shorting Sana Biotechnology shares can be evaluated.
Sana Biotechnology's "short interest ratio" (SIR)
Sana Biotechnology's "short interest ratio" (SIR) is the quantity of Sana Biotechnology shares currently shorted divided by the average quantity of Sana Biotechnology shares traded daily (recently around 1.6 million). Sana Biotechnology's SIR currently stands at 5.36. In other words for every 100,000 Sana Biotechnology shares traded daily on the market, roughly 5360 shares are currently held short.
To gain some more context, you can compare Sana Biotechnology's short interest ratio against those of similar companies.
However Sana Biotechnology's short interest can also be evaluated against the total number of Sana Biotechnology shares, or, against the total number of tradable Sana Biotechnology shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Sana Biotechnology's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Sana Biotechnology shares in existence, roughly 40 shares are currently held short) or 0.1063% of the tradable shares (for every 100,000 tradable Sana Biotechnology shares, roughly 106 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Sana Biotechnology.
Find out more about how you can short Sana Biotechnology stock.
Sana Biotechnology share dividends
We're not expecting Sana Biotechnology to pay a dividend over the next 12 months.
Sana Biotechnology overview
Sana Biotechnology, Inc. , a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops in vivo and ex vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease; and SC187 for heart failures. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc.
Sana Biotechnology in the news
Regents Of The University Of California Buys ironSource, Alibaba Group Holding, Sana Biotechnology Inc, Sells , Upstart Holdings Inc, RAPT Therapeutics Inc
Sana Obtains License To Beam Therapeutics' CRISPR Cas12b Gene Editing Technology
Sana Obtains License To Beam Therapeutics' CRISPR Cas12b Gene Editing Technology
Frequently asked questionsWhat percentage of Sana Biotechnology is owned by insiders or institutions?
Currently 12.241% of Sana Biotechnology shares are held by insiders and 74.601% by institutions. How many people work for Sana Biotechnology?
Latest data suggests 321 work at Sana Biotechnology. When does the fiscal year end for Sana Biotechnology?
Sana Biotechnology's fiscal year ends in December. Where is Sana Biotechnology based?
Sana Biotechnology's address is: 188 East Blaine Street, Seattle, WA, United States, 98020 What is Sana Biotechnology's ISIN number?
Sana Biotechnology's international securities identification number is: US7995661045
More guides on Finder
How to buy ProShares Bitcoin Strategy ETF (BITO)
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
How to buy The Real Good Food Company (RGF) stock when it goes public
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
How to buy Lulu’s Fashion Lounge Holdings (LVLU) stock when it goes public
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
How to buy Allarity Therapeutics (ALLR) stock when it goes public
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
How to buy Jupiter Neurosciences (JUNS) stock when it goes public
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
How to buy Mainz Biomed (MYNZ) stock when it goes public
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
How to buy Progressive Care stock when it goes public
Everything we know about the Progressive Care IPO, plus information on how to buy in.
How to buy Desert Peak Minerals (DPM) stock when it goes public
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
How to buy Vaxxinity (VAXX) stock when it goes public
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
How to buy Entrada Therapeutics (TRDA) stock when it goes public
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
Ask an Expert